This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Immunology  • Oncology  • Head & Neck Cancer  • Neoplasms of Head & Neck  • Dermatology  • Alert me on articles by topic

Walter T. Lee, MD; Hidemasa Tamai, MD; Peter Cohen, MD; Aysenur Meric Teker, MD; Suyu Shu, PhD

Arch Otolaryngol Head Neck Surg. 2008;134(6):608-613.

Objective  To investigate the therapeutic efficacy of fused dendritic-tumor cell hybrids against murine squamous cell carcinoma (SCC).

Design  Squamous cell carcinoma VII is a poorly immunogenic murine SCC tumor in C3H/HEN (H-2^K) mice. Subdermal tumors were established by inoculation in the mid abdomen of mice. Tumor diameters were measured with a Vernier caliper and used as an indication of treatment efficacy. Survival studies were performed on mice with 3-day pulmonary metastasis or subdermal tumors. Dendritic cells were generated from bone marrow and cultured for 8 days. Dendritic cells were harvested and mixed with cultured tumor cells in a 1:1 ratio. Cell fusion was achieved by exposing the cell mixture to an alternate electrical current to bring cells into alignment and close together, followed by a short direct electrical current pulse.

Subjects  Female C3H/HEN mice aged 8 to 12 weeks.

Interventions  Mice with 3-day established SCCVII tumors were vaccinated by inguinal intranodal injection of fusion cells (0.3 x 10⁶ per side). To support the development of antitumor immunity, mice were given adjuvant injections intraperitoneally. Anti-OX40R monoclonal antibodies or interleukin 12 were used. Treatment groups included no treatment, anti-OX40R monoclonal antibodies or adjuvant IL-12 alone, fusion cells alone, and fusion cells with adjuvant treatment.

Main Outcome Measures  Tumor size and overall survival.

Results  Mice treated with adjuvant treatment or fusion cells alone did not show a statistical difference in tumor growth when compared with controls. In contrast, fusion cells with adjuvant treatment demonstrated a significant decrease in tumor size when compared with nontreated mice (P < .001). Treatment with fusion cells also resulted in increased survival in the pulmonary metastasis and subdermal tumor models.

Conclusion  Immunotherapy with fused dendritic-tumor cell hybrids can significantly affect 3-day established sSCC VII tumor growth.

Author Affiliations: Center for Surgery Research (Drs Lee, Cohen, Teker, and Shu) and Head and Neck Institute (Drs Lee and Teker), Cleveland Clinic, Cleveland Ohio; and Surgery and Oncology of the Digestive System, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan (Dr Tamai).